We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
101
DELISTED
Masimo
MASI
$2.43M 0.15%
19,476
+4,676
+32% +$519K
CSLT
102
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.4M 0.15%
888,842
+601,502
+209% +$2.13M
SRPT icon
103
Sarepta Therapeutics
SRPT
$1.82B
$2.12M 0.13%
+13,100
New +$1.79M
AMRX icon
104
Amneal Pharmaceuticals
AMRX
$5.7B
$2.11M 0.13%
95,000
+20,000
+27% +$421K
ONC
105
BeOne Medicines Ltd
ONC
$32.4B
$2M 0.13%
11,620
+120
+1% +$20.2K
PODD icon
106
Insulet
PODD
$11.4B
$1.91M 0.12%
18,000
– –
RGNX icon
107
Regenxbio
RGNX
$534M
$1.76M 0.11%
23,300
-500
-2% -$36K
BLUE
108
DELISTED
bluebird bio
BLUE
$1.66M 0.11%
880
-116
-12% -$240K
ANGO icon
109
AngioDynamics
ANGO
$558M
$1.65M 0.1%
75,700
– –
SAGE
110
DELISTED
Sage Therapeutics
SAGE
$1.58M 0.1%
11,200
-900
-7% -$139K
AGIO icon
111
Agios Pharmaceuticals
AGIO
$2.36B
$1.53M 0.1%
19,861
-8,950
-31% -$720K
TSRO
112
DELISTED
TESARO, Inc.
TSRO
$1.5M 0.1%
38,550
+13,300
+53% +$470K
IRWD icon
113
Ironwood Pharmaceuticals
IRWD
$635M
$1.47M 0.09%
+94,804
New +$1.5M
AET
114
DELISTED
Aetna Inc
AET
$1.44M 0.09%
7,100
– –
ARNA
115
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.42M 0.09%
30,817
-600
-2% -$24.3K
CLLS
116
Cellectis
CLLS
$265M
$1.4M 0.09%
49,600
-1,000
-2% -$28.7K
SYNH
117
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$1.35M 0.09%
26,156
-500
-2% -$24.5K
TEVA icon
118
Teva Pharmaceuticals
TEVA
$37.3B
$1.29M 0.08%
60,000
-30,000
-33% -$696K
PFE icon
119
Pfizer
PFE
$143B
$1.29M 0.08%
30,777
– –
EGRX
120
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.25M 0.08%
18,000
-15,000
-45% -$1.14M
ITCI
121
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.19M 0.08%
54,600
-25,300
-32% -$529K
ACAD icon
122
Acadia Pharmaceuticals
ACAD
$4.38B
$1.18M 0.08%
+57,000
New +$897K
MRTX
123
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.18M 0.07%
25,000
-500
-2% -$27.8K
GWPH
124
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.15M 0.07%
6,629
-550
-8% -$79.3K
MCK icon
125
McKesson
MCK
$98.5B
$1.13M 0.07%
8,503
-3,347
-28% -$436K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.